Melanoma is the most lethal malignancy of the skin. Immunotherapy has contributed to improved survival in melanoma patients, yet the mechanisms explaining differences in efficacy have not been elucidated. In previous studies our group found an immune signature that predicts response to antiPD1 immunotherapy. On the other hand, melanoma genomics have been extensively studied, but data regarding protein expression are still scarce. We have performed a genomics plus proteomics analysis of advanced melanoma samples aiming to find mechanisms of resistance to antiPD1.